TY  - BOOK
AU  - Chen, Fang
AU  - Lipinski, Michael J
AU  - Pendyala, Lakshmana K
AU  - Torguson, Rebecca
AU  - Waksman, Ron
TI  - Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin
SN  - 0021-9150
KW  - *Diabetes Mellitus, Type 2/dt [Drug Therapy]
KW  - *Metformin/tu [Therapeutic Use]
KW  - *Percutaneous Coronary Intervention
KW  - *Stents/ae [Adverse Effects]
KW  - *Thrombosis/ci [Chemically Induced]
KW  - Aged
KW  - Drug-Eluting Stents/ae [Adverse Effects]
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Paclitaxel/ad [Administration & Dosage]
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
KW  - Observational Study
N2  - CONCLUSION: In NIDDM patients, metformin use or stent type following DES placement did not increase stent thrombosis and MACE rates.Copyright � 2014 Elsevier Ireland Ltd. All rights reserved; METHODS: We assessed the impact of metformin and stent type on stent thrombosis, MACE, and death in NIDDM patients following DES placement. Of the 1201 patients included, 74.8% received LES, 25.2% received paclitaxel-eluting stents (PES), and 55% were taking metformin; OBJECTIVE: Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis. Therefore, we assessed the impact of metformin on stent thrombosis and major adverse cardiovascular events (MACE) in non-insulin-dependent diabetes mellitus (NIDDM) patients who receive drug-eluting stents (DES); RESULTS: There was no difference in stent thrombosis, regardless of stent type or metformin use. While Kaplan-Meier curves demonstrated reduced MACE (p = 0.007) and death (p = 0.006) with metformin use, multivariate analysis demonstrated that stent type and metformin use were not associated with outcome
UR  - http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.919
ER  -